Physician profile
Francesse M Bataille
NPI 1255371613
$108,780.10
in general payments reported to CMS, 2019-2025
15 companies · $108K in 2025
The $108K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $57.83 · 2021: $114 · 2023: $171 · 2024: $72.42 · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $108K · Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $108,000.00 |
| Food and Beverage | $308.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $108,000.00 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $185.90 | 2019-2021 | |
| Amgen INC. | $142.82 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $111.67 | 2019 | |
| Coala Life INC | $75.06 | 2023 | Coala Heart Monitor |
| Medtronic, INC. | $74.69 | 2023 | Venaseal |
| Abbvie INC. | $38.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.40 | 2021 | |
| Lilly USA, LLC | $22.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.81 | 2023 | Eliquis |
| Astellas Pharma US INC | $19.89 | 2019 | |
| Axsome Therapeutics, INC. | $19.44 | 2025 | Auvelity |
| Novo Nordisk INC | $11.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.39 | 2019 | |
| Allergan, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesse Bataille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.